
-
McLaughlin-Levrone, Thomas cruise to wins at opening Grand Slam Track
-
US cardinal defrocked for sex abuse dies at 94
-
Lula admits 'still a lot to do' for Indigenous Brazilians
-
England, Germany and Spain on mark in women's Nations League
-
Judge orders return to US of Salvadoran man deported in error
-
Amadou of Malian blind music duo dies aged 70
-
Freeman hat-trick eases Northampton into Champions Cup quarters with Clermont win
-
Defiant Trump dismisses stock market's tariff plunge
-
Musiala injury sours Bayern win at Augsburg
-
Peruvian schoolkids living in fear of extortion gangs
-
Top seed Pegula rallies to oust defending champ Collins in Charleston
-
Amadou of Malian blind music duo Amadou & Mariam dies aged 70
-
California to defy Trump's tariffs to allay global trade fears
-
Bayern's Musiala subbed off with injury days out from Inter clash
-
Russian strike kills 16 in Ukraine leader's home city, children among dead
-
NBA fines Grizzlies' Morant for imaginary gun gesture
-
Trump tariffs offer opportunity for China
-
UK comedian Russell Brand charged with rape
-
Marsh, Markram help Lucknow edge Mumbai in IPL
-
Israel attorney general accuses PM of 'conflict of interest' in security chief dismissal
-
Emery glad to see Rashford make landmark appearance
-
Sean 'Diddy' Combs faces more charges ahead of criminal trial
-
Russian missile strike kills 14 in Ukraine leader's home city
-
Trump's tariff Big Bang puts global economy under threat
-
I Am Maximus backed for National as Mullins hot streak continues
-
2014 World Cup winner Hummels to retire at season's end
-
Intercommunal violence kills dozens in central Nigeria
-
Nigerian, S. African music saw 'extraordinary growth' in 2024: Spotify
-
Russell Brand: From Hollywood star to rape suspect
-
France soccer star Mbappe unveiled in London... in waxwork form
-
Trump goads China as global trade war escalates
-
Israel expands Gaza ground offensive, hits Hamas in Lebanon
-
TikTok faces new US deadline to ditch Chinese owner
-
US Fed Chair warns tariffs will likely raise inflation, cool growth
-
Mbappe among three Real Madrid players fined for 'indecent conduct'
-
How can the EU respond to Trump tariffs?
-
Canada loses jobs for first time in 3 years as US tariffs bite
-
Real Madrid and Barcelona respect each other, says Ancelotti
-
Nations divided ahead of decisive week for shipping emissions
-
Trump goads China after Beijing retaliates in global trade war
-
Arteta urges Arsenal to enjoy "beautiful" run-in despite injury woes
-
London mayor gets new powers to revive capital's ailing nightlife
-
Italy's ski star Brignone takes on 'new challenge' after serious leg injury
-
Amorim in a 'rush' to succeed at Man Utd
-
PSG coach Luis Enrique targets unbeaten season
-
Duterte victims seeking 'truth and justice': lawyer
-
UK comedian and actor Russell Brand charged with rape
-
Postecoglou 'falling out of love' with football due to VAR
-
US hiring beats expectations in March as tariff uncertainty brews
-
'Unique' De Bruyne one of the greats, says Guardiola
RBGPF | 1.48% | 69.02 | $ | |
SCS | -0.56% | 10.68 | $ | |
JRI | -7.19% | 11.96 | $ | |
NGG | -5.25% | 65.93 | $ | |
RELX | -6.81% | 48.16 | $ | |
GSK | -6.79% | 36.53 | $ | |
BTI | -5.17% | 39.86 | $ | |
CMSD | 0.7% | 22.83 | $ | |
BCC | 0.85% | 95.44 | $ | |
RIO | -6.88% | 54.67 | $ | |
CMSC | 0.13% | 22.29 | $ | |
BCE | 0.22% | 22.71 | $ | |
VOD | -10.24% | 8.5 | $ | |
RYCEF | -18.79% | 8.25 | $ | |
AZN | -7.98% | 68.46 | $ | |
BP | -10.43% | 28.38 | $ |

EU watchdog approves vaccine targeting Omicron sub-variants
The EU's medicines watchdog on Monday approved a vaccine specifically targeting the new and contagious types of the Omicron variant amid fears of a new wave of Covid-19 winter infections.
The so-called "bivalent" jab, made by Pfizer/BioNTech, is directed at the highly infectious BA.4 and BA.5 types of the variant and is the first of its kind to be approved within the 27-nation bloc.
"This recommendation will further extend the arsenal of available vaccines to protect people against Covid-19 as the pandemic continues and new waves of infections are anticipated in the cold season," the European Medicines Agency (EMA) said.
The vaccine also targets "the original strain of SARS-CoV-2" and comes 11 days after the Amsterdam-based drug watchdog approved vaccines by Pfizer and Moderna against the Omicron BA.1 variant.
The latest shot is aimed at people over 12 and who have already received at least one primary vaccination against the coronavirus, and it is an adaptive version of Pfizer's original Comirnaty vaccine.
European nations have been keen to rush through the new generation of jabs so they can start booster campaigns ahead of a feared Covid surge in the latter part of this year.
The latest vaccines "better match the circulating variants of SARS-CoV-2 and are expected to provide broader protection against different variants," the EMA said.
"Prompt assessment of the available data on these adapted vaccines will enable their timely deployment in the autumn vaccination campaigns," it added.
The EMA's recommendation -- which will now be sent to the European Commission for a final decision -- was specifically based on clinical data from Pfizer's vaccines aimed at the original virus and the Omicron BA.1 variant.
- New wave feared -
"Apart from containing mRNA matching different, but closely related, Omicron sub-variants, Comirnaty Original/Omicron BA.4-5 and Comirnaty Original/Omicron BA.1 have the same composition," the EMA said.
Pfizer's vaccine works on the principle of tiny molecules carrying instructions for the human body to temporarily produce spike proteins similar to those found on the coronavirus -- and which it uses to enter the body's cells.
The body's immune system recognises the spike protein as foreign and activates natural defences against them.
When a person then comes in contact with the real virus, the body's immune system will also recognise and attack it.
The United States authorised its first anti-Omicron vaccines late last month, approving Pfizer and Moderna jabs for the BA.4 and BA.5 strains.
Britain authorised the Moderna vaccine for the BA.1 type in mid-August.
While the original vaccines, approved nearly two years ago provided some protection against newer coronavirus variants, the race had been on to come out with a newer group of vaccines that also target the milder but more infectious Omicron strains.
While previous "variants of concern" like Alpha and Delta eventually petered out, Omicron and its sub-lineages have dominated throughout 2022.
The BA.4 and BA.5 types have in particular helped to drive a wave of new cases of the disease in Europe and the United States in recent months.
All Omicron variants tend to have a milder disease course as they settle less in the lungs and more in the upper nasal passages, causing symptoms like fever, tiredness and loss of smell.
jhe/rox
M.Carneiro--PC